These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12783591)

  • 1. Prescription drugs and pregnancy.
    Webster WS; Freeman JA
    Expert Opin Pharmacother; 2003 Jun; 4(6):949-61. PubMed ID: 12783591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescription of hazardous drugs during pregnancy.
    Malm H; Martikainen J; Klaukka T; Neuvonen PJ
    Drug Saf; 2004; 27(12):899-908. PubMed ID: 15366977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry.
    Ephross SA; Sinclair SM
    Headache; 2014; 54(7):1158-72. PubMed ID: 24805878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescriptions filled during pregnancy for drugs with the potential of fetal harm.
    Kulaga S; Zargarzadeh AH; Bérard A
    BJOG; 2009 Dec; 116(13):1788-95. PubMed ID: 19832828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescribing in pregnancy and during breast feeding: using principles in clinical practice.
    Henderson E; Mackillop L
    Postgrad Med J; 2011 May; 87(1027):349-54. PubMed ID: 21273359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug use in pregnancy: how to avoid problems.
    Rao JM; Arulappu R
    Drugs; 1981 Nov; 22(5):409-14. PubMed ID: 6120825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maternal use of prescribed drugs associated with recognized fetal adverse drug reactions.
    Piper JM; Baum C; Kennedy DL; Price P
    Am J Obstet Gynecol; 1988 Nov; 159(5):1173-7. PubMed ID: 2461078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human experiences related to adverse drug reactions to the fetus or neonate from some maternally administered drugs.
    Shirkey HC
    Adv Exp Med Biol; 1972; 27():17-30. PubMed ID: 4140679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety of sumatriptan and naratriptan in pregnancy: what have we learned?
    Cunnington M; Ephross S; Churchill P
    Headache; 2009; 49(10):1414-22. PubMed ID: 19804390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of antirheumatic drugs in mothers and fathers before and during pregnancy-a population-based cohort study.
    Viktil KK; Engeland A; Furu K
    Pharmacoepidemiol Drug Saf; 2009 Aug; 18(8):737-42. PubMed ID: 19504626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drugs associated with teratogenic mechanisms. Part II: a literature review of the evidence on human risks.
    van Gelder MM; de Jong-van den Berg LT; Roeleveld N
    Hum Reprod; 2014 Jan; 29(1):168-83. PubMed ID: 24108217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescription drug use in pregnancy: a retrospective, population-based study in British Columbia, Canada (2001-2006).
    Daw JR; Mintzes B; Law MR; Hanley GE; Morgan SG
    Clin Ther; 2012 Jan; 34(1):239-249.e2. PubMed ID: 22169049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer chemotherapeutic agents as human teratogens.
    Selig BP; Furr JR; Huey RW; Moran C; Alluri VN; Medders GR; Mumm CD; Hallford HG; Mulvihill JJ
    Birth Defects Res A Clin Mol Teratol; 2012 Aug; 94(8):626-50. PubMed ID: 22851372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graves'-Basedow disease in pregnancy. New trends in the management and guidance to reduce the risk of birth defects caused by antithyroid drugs.
    Laurberg P; Andersen SL
    Nuklearmedizin; 2015; 54(3):106-11. PubMed ID: 26105719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiepileptic medication and oral contraceptive interactions: a national survey of neurologists and obstetricians.
    Krauss GL; Brandt J; Campbell M; Plate C; Summerfield M
    Neurology; 1996 Jun; 46(6):1534-9. PubMed ID: 8649543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk minimization practices for pregnancy prevention: understanding risk, selecting tools.
    Uhl K; Trontell A; Kennedy D
    Pharmacoepidemiol Drug Saf; 2007 Mar; 16(3):337-48. PubMed ID: 16953517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescribing during pregnancy and lactation with reference to the Swedish classification system. A population-based study among Danish women.
    Olesen C; Sørensen HT; de Jong-van den Berg L; Olsen J; Steffensen FH; The Euromap Group
    Acta Obstet Gynecol Scand; 1999 Sep; 78(8):686-92. PubMed ID: 10468060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study.
    Nezvalová-Henriksen K; Spigset O; Nordeng H
    Headache; 2010 Apr; 50(4):563-75. PubMed ID: 20132339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern?
    Thorne C; Newell ML
    Drug Saf; 2007; 30(3):203-13. PubMed ID: 17343429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.